Baveno VII Criteria — Compensated Advanced Chronic Liver Disease (cACLD)
Baveno VII consensus (de Franchis 2022) for non-invasive identification of cACLD and clinically significant portal hypertension (CSPH) using liver stiffness measurement (LSM) by transient elastography and platelet count. 'Rule of 5' for LSM categories.
Score interpretation
→ No surveillance for portal hypertension required. Manage underlying liver disease; lifestyle, alcohol cessation, weight.
→ Annual LSM + platelets to monitor progression. Six-monthly HCC US surveillance if cirrhosis confirmed.
→ Endoscopy may be deferred; start non-selective β-blocker (carvedilol 6.25 mg BD preferred) for primary prevention of decompensation. Six-monthly HCC surveillance. Treat aetiology aggressively.
→ Carvedilol immediately; surveillance OGD if β-blocker contraindicated/intolerant; consider TIPS for refractory ascites/variceal bleeding; transplant assessment if MELD trending up.
Interpretation bands for the Baveno VII. Apply clinical judgement and local guidance.
References
Related
Curated clinical cross-links plus same-class fallbacks.
- Propranolol (Portal Hypertension) · Antihypertensive
- Carvedilol (Portal Hypertension) · Non-Selective Beta-Blocker with Alpha₁-Blocking Activity
- Methyldopa (Chronic Hypertension in Pregnancy) · Centrally Acting Antihypertensive
- Amlodipine · Dihydropyridine Calcium Channel Blocker — Raynaud's / Peripheral Vascular Disease / Hypertension
- Hydralazine · Direct-Acting Vasodilator — Hypertensive Emergency / Chronic Hypertension
- Selexipag · Pulmonary Arterial Hypertension
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.